Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...

In this week’s InnovationRx newsletter, tariffs could hit medical devices, a gene therapy company that helps blind kids see ...

AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for ...